An Anti–CLL-1 Antibody–Drug Conjugate for the Treatment of Acute Myeloid Leukemia

Abstract

Collectively, our data suggest that an anti-CLL-1-ADC has the potential to become an effective and safer treatment for AML in humans, by reducing and allowing for faster recovery from initial cytopenias than the current generation of ADCs for AML.